Navigating Brexit – The UK’s withdrawal from the EU

Pharma’s Predicament

Pharma’s predicament is the uncertainty and the sheer magnitude of the task that Brexit faces it with.  The prospect of the UK becoming a so-called ‘third country’, after so many years of immersion in the EU regulatory system for Pharma, is daunting.  Pharma has a lot to prepare for and reconfigure to ensure the on-going validity of its Marketing Authorisations, the compliance of its supply chain, manufacturing and procurement, as well as in many cases, the integrity of its orphan medicinal product designations and SME registrations. PharmaLex has established a dedicated Brexit task force to provide  pragmatic advice to mitigate the uncertainty and risks.  As a global consultancy, PharmaLex is ideally placed to implement/review your tactical or strategic Brexit contingency plans Contact our team to discuss more –  please contact us at +353 1 846 47 42 or contactirl@pharmalex.com. Download our PDF  version BREXIT – We help you to prepare

Top Tips – Building your ISO Quality Management System
24th April 2019

EU Guidance on the Implementation of the Medical Devices and In-Vitro Diagnostic Medical Devices Regulations
3rd April 2019

EU Advice on Fluroquinolone Antibiotics – Use and Adverse Reactions
28th March 2019

European Commission Goals for Sustainability in the Pharmaceutical Industry
21st March 2019

New Guidance on Classification of Good Manufacturing Practice Deficiencies
11th March 2019

European Commission issued QC Test Exemption for the EU post March 29th, 2019
6th March 2019